Mayo Clinic Laboratory and Pathology Research Roundup: October 14

By Samantha Rossi • October 14, 2019

Share this:

The research roundup provides an overview of the past week’s research from Mayo Clinic Laboratories consultants, including featured abstracts and a complete list of published studies and reviews.

Featured Abstract

A Phase Two Study of Pembrolizumab Combined with Chemoradiotherapy as Initial Treatment for Anaplastic Thyroid Cancer.

Anaplastic thyroid cancer (ATC) has poor prognosis with median overall survival ~6 months. We previously reported high PD-1/PDL-1 staining in ATC, raising the possibility of the productive application of the immunotherapeutic pembrolizumab. However, finding pembrolizumab to have anecdotally limited single-agent activity in ATC, we sought to alternatively define whether pembrolizumab might synergistically combine with chemoradiotherapy as initial ATC therapy. Via Thyroid.

Read more.

Published to PubMed This Week

• Uterine Leiomyoma.
  Mayo Clinic Proceedings
• 78-Year-Old Woman with Intermittent Chest Pain and Palpitations.
  Mayo Clinic Proceedings
• Male Breast Cancer in the United States: Treatment Patterns and Prognostic Factors in the 21st Century.
  Cancer
• In Vivo Assessment of High-Molecular-Weight Polyethylene Core Suture Tape for Intra-Articular Ligament Reconstruction: An Animal Study.
  The Bone and Joint Journal
• Transthyretin Amyloidosis: Putting Myopathy on the Map.
  Muscle and Nerve
• Sinonasal Mucosal Vasculature in Yellow Nail Syndrome and Chronic Rhinosinusitis with or without Polyps.
  International Forum of Allergy and Rhinology
• Correction To: Hybridization Capture-Based Next-Generation Sequencing Reliably Detects FLT3 Mutations and Classifies FLT3-Internal Tandem Duplication Allelic Ratio in Acute Myeloid Leukemia: A Comparative Study to Standard Fragment Analysis.
  Modern Pathology

Samantha Rossi

Samantha Rossi is a Digital Marketing Manager at Mayo Clinic Laboratories. She supports marketing strategies for product management and specialty testing. Samantha has worked at Mayo Clinic since 2019.